Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants

AIDS

Volumn 22, Issue 13, 2008, Pages 1633-1640

  Bae, Woong Hwan ^a   Wester, Carolyn ^b,c   Smeaton, Laura M ^d   Shapiro, Roger L ^b,c,e   Lockman, Shahin ^b,c,f   Onyait, Kenneth ^b   Thior, Ibou ^b   Essex, Max ^b,c,g  

^a HARVARD COLLEGE   (United States)

^b BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^c Department of Immunology and Infectious Diseases ^*  (United States)

^d CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g Harvard AIDS Institute   (United States)

Author keywords

Botswana; Breastfeeding; Highly active antiretroviral therapy; HIV; Mother to child transmission; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; NEVIRAPINE; PLACEBO; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ARTIFICIAL MILK; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BOTSWANA; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; KAPLAN MEIER METHOD; LIVER TOXICITY; MAJOR CLINICAL STUDY; MATERNAL TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PERINATAL DRUG EXPOSURE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VERTICAL TRANSMISSION; VIRUS LOAD; BLOOD; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; IMMUNOLOGY; MALE; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE;

ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BOTSWANA; BREAST FEEDING; COHORT STUDIES; DISEASE TRANSMISSION, VERTICAL; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUTROPENIA; NEVIRAPINE; PLATELET COUNT; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; ZIDOVUDINE;

EID: 52249108495     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328307a029     Document Type: Article

References (21)

1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sulli-van MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180.
2. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 -infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-494.
3. Brogly SB, Ylitalo N, Mofenson LM, OleskeJ, Van Dyke R, Crain MJ, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007; 21:929-938.
4. Pacheco SE, McIntosh K, Lu M, Mofenson LM, Diaz C, Foca M, et al. Effect of perinatal antiretroviral drug exposure on hema-tologic values in HIV-uninfected children: An analysis of the women and infants transmission study. J Infect Dis 2006; 194:1089-1097.
5. CulnaneM, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999; 281:151-157.
6. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr 2002; 30:200-215.
7. Le ChenadecJ , Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17:2053-2061.
8. Bunders MJ, Bekker V, Scherpbier HJ, Boer K, Godfried M, KuijpersTW. Haematological parameters of HI V-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr 2005; 94:1571-1577.
9. Feiterna-Sperling C, Weizsaecker K, Buhrer C, Casteleyn S, Loui A, Schmitz T, et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. J Acquir Immune Defic Syndr 2007; 45:43-51.
10. European Collaborative Study. Levels and patterns of neutro-phil cell counts over the first 8 years of life in children of HI V-1 -infected mothers. AIDS 2004; 18:2009-2017.
11. ThorneC, Newell ML. Safety of agentsused to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf 2007; 30:203-213.
12. Bunders M, Lugada E, Mermin J, Downing R, Were W, Thorne C, Newell ML. Within and between race differences in lymphocyte, CD4R, CD8R and neutrophil levels in HIV-uninfected children with or without HIV exposure in Europe and Uganda. Ann Trop Paediatr 2006; 26:169-179.
13. Wells J, Shetty AK, Stranix L, Falkovitz-Halpern MS, ChipatoT, Nyoni N, et al. Range of normal neutrophil counts in healthy Zimbabwean infants: implications for monitoring antiretroviral drug toxicity. J Acquir Immune Defic Syndr 2006; 42:460-463.
14. Bunders M, Cortina-Borja M, Newell ML. Age-related standards for total lymphocyte, CD4R and CD8R T cell counts in children born in Europe. Pediatr Infect Dis J 2005; 24:595-600.
15. Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 2006; 20:1281-1288.
16. Thior I, Lockman S, Smeaton LM, Shapiro RL, WesterC, Heymann SJ, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006; 296:794-805.
17. Division of AIDS (DAIDS) toxicity table for grading severity of pediatric (≤3 months of age) adverse experiences. http:// rcc.tech-res.com/ DAIDS%20RCC%20Forms/ToxicityTables-Pediatric-Under3MonthsOld-VPRP-v02.pdf. [Accessed 18 February 2008].
18. Division of AIDS (DAIDS) toxicity table for grading severity of pediatric (>3 months of age) adverse experiences. http:// rcc.tech-res.com/ DAIDS%20RCC%20Forms/ToxicityTable-s-Pediatric-Over3MonthsOld-VPRP-v03.pdf. [Accessed 18 February 2008].
19. Mussi-Pinhata MM, Rego MA, Freimanis L, Kakehasi FM, Ma-chado DM, Cardoso EM, Read JS. Maternal antiretrovirals and hepatic enzyme, hematologic abnormalities among human immunodeficiency virus type 1-uninfected infants: the NISDI perinatal study. Pediatr Infect Dis J 2007; 26:1032-1037.
20. Shetty AK, Coovadia HM, Mirochnick MM, Maldonado Y, Mofenson LM, Eshleman SH, et al. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr 2003; 34:482-490.
21. Shapiro RL, Holland DT, Capparelli E, Lockman S, Thior I, Wester C, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192:720-727.